Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury - Renibus plans to enroll 126 subjects at up to 20 sites across the United States, Canada, Australia, and New Zealand DALLAS, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics®...

Rénibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference DALLAS, Texas, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Rénibus Therapeutics, Inc., a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease,...

Renibus Therapeutics Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant -With no currently approved therapies for the prevention or treatment of platinum-induced toxicity, RBT-3 has the potential to fill a critical unmet medical need Dallas, Texas, Feb. 16, 2021 ...

Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Annual Congress Dallas, June 09, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc, a clinical-stage biotechnology company, is pleased to announce that data highlighting the translation of the mechanism of action...